The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis
Background: The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission. Objective: This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2024-06, Vol.30 (7), p.888-892 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 892 |
|---|---|
| container_issue | 7 |
| container_start_page | 888 |
| container_title | Multiple sclerosis |
| container_volume | 30 |
| creator | Krieger, Stephen C Sinks, Susie Huang, Furong Steverson, Julie Kalina, Tamar J White, Kurt Avila, Robin L |
| description | Background:
The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission.
Objective:
This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive anti-JCV antibody serostatus before and during the pandemic.
Methods:
Data from TYSABRI Outreach: Unified Commitment to Health (TOUCH) for 22,375 US patients treated with natalizumab with anti-JCV antibody records were assessed in epochs annually from 2017 to 2022.
Results:
Pre-pandemic anti-JCV antibody serostatus change was observed for 7.4%–7.7%. During the first and second years of the pandemic, 7.3% and 7.2% of patients’ serostatus changed, respectively.
Conclusion:
The proportion of patients with anti-JCV antibody serostatus change did not significantly differ during the first 2 years of the pandemic compared with prior years. In contrast to seasonal influenza, masking and social distancing had no discernable effect on JCV serostatus change. |
| doi_str_mv | 10.1177/13524585241232274 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11134982</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_13524585241232274</sage_id><sourcerecordid>3061374750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-1998ab35408003dc76445987a60a728790ad7d66a65646ccc7fe1251b3f93023</originalsourceid><addsrcrecordid>eNp1kUtuFDEQhi0EIiFwADbIEhs2HfxqP1YIDQQSRcqCga3lcbtnHHXbje0OYscdsuZynAS3JgkvsbHL-r_6q8oFwFOMjjEW4iWmLWGtrAcmlBDB7oFDzIRokBLofo2r3izAAXiU8yVCSAjaPgQHVDLEJZGH4Pt656AfJ2MLjD3M0XozwM7nYoL1YQtHZ_KcXIYxQBOK__Ht-mwFr3yaM8wuxQqWGtqdCdtKbVwfk6tkB7s5LQalFlhdfDp902AFpyq40VvoA_z4oT6Ld6Fk-MWXHRznofhpcDDbYXH2-TF40Jshuyc39xFYn7xdr9435xfvTlevzxvLsCrVWEmzoS1DEiHaWcEZa5UUhiMjiBQKmU50nBvecsattaJ3mLR4Q3tFEaFH4NXedpo3o-tsbSmZQU_JjyZ91dF4_acS_E5v45XGGFOm5OLw4sYhxc-zy0WPPls3DCa4OGdNFCWIYMJURZ__hV7GOYU6nqaIYyqYaFGl8J6y9SNycv1dNxjpZfn6n-XXnGe_j3GXcbvtChzvgWy27lfZ_zv-BKHVuOY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3061374750</pqid></control><display><type>article</type><title>The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Krieger, Stephen C ; Sinks, Susie ; Huang, Furong ; Steverson, Julie ; Kalina, Tamar J ; White, Kurt ; Avila, Robin L</creator><creatorcontrib>Krieger, Stephen C ; Sinks, Susie ; Huang, Furong ; Steverson, Julie ; Kalina, Tamar J ; White, Kurt ; Avila, Robin L</creatorcontrib><description>Background:
The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission.
Objective:
This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive anti-JCV antibody serostatus before and during the pandemic.
Methods:
Data from TYSABRI Outreach: Unified Commitment to Health (TOUCH) for 22,375 US patients treated with natalizumab with anti-JCV antibody records were assessed in epochs annually from 2017 to 2022.
Results:
Pre-pandemic anti-JCV antibody serostatus change was observed for 7.4%–7.7%. During the first and second years of the pandemic, 7.3% and 7.2% of patients’ serostatus changed, respectively.
Conclusion:
The proportion of patients with anti-JCV antibody serostatus change did not significantly differ during the first 2 years of the pandemic compared with prior years. In contrast to seasonal influenza, masking and social distancing had no discernable effect on JCV serostatus change.</description><identifier>ISSN: 1352-4585</identifier><identifier>ISSN: 1477-0970</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/13524585241232274</identifier><identifier>PMID: 38406828</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Antibodies, Viral - blood ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - immunology ; COVID-19 - prevention & control ; Epidemiology ; Female ; Humans ; Immunologic Factors - therapeutic use ; JC Virus - immunology ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Natalizumab - therapeutic use ; Pandemics ; Physical Distancing ; SARS-CoV-2 - immunology ; Short Report ; United States - epidemiology</subject><ispartof>Multiple sclerosis, 2024-06, Vol.30 (7), p.888-892</ispartof><rights>The Author(s), 2024</rights><rights>The Author(s), 2024 2024 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c419t-1998ab35408003dc76445987a60a728790ad7d66a65646ccc7fe1251b3f93023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/13524585241232274$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/13524585241232274$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,21824,27929,27930,43626,43627</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38406828$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krieger, Stephen C</creatorcontrib><creatorcontrib>Sinks, Susie</creatorcontrib><creatorcontrib>Huang, Furong</creatorcontrib><creatorcontrib>Steverson, Julie</creatorcontrib><creatorcontrib>Kalina, Tamar J</creatorcontrib><creatorcontrib>White, Kurt</creatorcontrib><creatorcontrib>Avila, Robin L</creatorcontrib><title>The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission.
Objective:
This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive anti-JCV antibody serostatus before and during the pandemic.
Methods:
Data from TYSABRI Outreach: Unified Commitment to Health (TOUCH) for 22,375 US patients treated with natalizumab with anti-JCV antibody records were assessed in epochs annually from 2017 to 2022.
Results:
Pre-pandemic anti-JCV antibody serostatus change was observed for 7.4%–7.7%. During the first and second years of the pandemic, 7.3% and 7.2% of patients’ serostatus changed, respectively.
Conclusion:
The proportion of patients with anti-JCV antibody serostatus change did not significantly differ during the first 2 years of the pandemic compared with prior years. In contrast to seasonal influenza, masking and social distancing had no discernable effect on JCV serostatus change.</description><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>JC Virus - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Natalizumab - therapeutic use</subject><subject>Pandemics</subject><subject>Physical Distancing</subject><subject>SARS-CoV-2 - immunology</subject><subject>Short Report</subject><subject>United States - epidemiology</subject><issn>1352-4585</issn><issn>1477-0970</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1kUtuFDEQhi0EIiFwADbIEhs2HfxqP1YIDQQSRcqCga3lcbtnHHXbje0OYscdsuZynAS3JgkvsbHL-r_6q8oFwFOMjjEW4iWmLWGtrAcmlBDB7oFDzIRokBLofo2r3izAAXiU8yVCSAjaPgQHVDLEJZGH4Pt656AfJ2MLjD3M0XozwM7nYoL1YQtHZ_KcXIYxQBOK__Ht-mwFr3yaM8wuxQqWGtqdCdtKbVwfk6tkB7s5LQalFlhdfDp902AFpyq40VvoA_z4oT6Ld6Fk-MWXHRznofhpcDDbYXH2-TF40Jshuyc39xFYn7xdr9435xfvTlevzxvLsCrVWEmzoS1DEiHaWcEZa5UUhiMjiBQKmU50nBvecsattaJ3mLR4Q3tFEaFH4NXedpo3o-tsbSmZQU_JjyZ91dF4_acS_E5v45XGGFOm5OLw4sYhxc-zy0WPPls3DCa4OGdNFCWIYMJURZ__hV7GOYU6nqaIYyqYaFGl8J6y9SNycv1dNxjpZfn6n-XXnGe_j3GXcbvtChzvgWy27lfZ_zv-BKHVuOY</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Krieger, Stephen C</creator><creator>Sinks, Susie</creator><creator>Huang, Furong</creator><creator>Steverson, Julie</creator><creator>Kalina, Tamar J</creator><creator>White, Kurt</creator><creator>Avila, Robin L</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240601</creationdate><title>The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis</title><author>Krieger, Stephen C ; Sinks, Susie ; Huang, Furong ; Steverson, Julie ; Kalina, Tamar J ; White, Kurt ; Avila, Robin L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-1998ab35408003dc76445987a60a728790ad7d66a65646ccc7fe1251b3f93023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>JC Virus - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Natalizumab - therapeutic use</topic><topic>Pandemics</topic><topic>Physical Distancing</topic><topic>SARS-CoV-2 - immunology</topic><topic>Short Report</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krieger, Stephen C</creatorcontrib><creatorcontrib>Sinks, Susie</creatorcontrib><creatorcontrib>Huang, Furong</creatorcontrib><creatorcontrib>Steverson, Julie</creatorcontrib><creatorcontrib>Kalina, Tamar J</creatorcontrib><creatorcontrib>White, Kurt</creatorcontrib><creatorcontrib>Avila, Robin L</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krieger, Stephen C</au><au>Sinks, Susie</au><au>Huang, Furong</au><au>Steverson, Julie</au><au>Kalina, Tamar J</au><au>White, Kurt</au><au>Avila, Robin L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>30</volume><issue>7</issue><spage>888</spage><epage>892</epage><pages>888-892</pages><issn>1352-4585</issn><issn>1477-0970</issn><eissn>1477-0970</eissn><abstract>Background:
The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission.
Objective:
This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive anti-JCV antibody serostatus before and during the pandemic.
Methods:
Data from TYSABRI Outreach: Unified Commitment to Health (TOUCH) for 22,375 US patients treated with natalizumab with anti-JCV antibody records were assessed in epochs annually from 2017 to 2022.
Results:
Pre-pandemic anti-JCV antibody serostatus change was observed for 7.4%–7.7%. During the first and second years of the pandemic, 7.3% and 7.2% of patients’ serostatus changed, respectively.
Conclusion:
The proportion of patients with anti-JCV antibody serostatus change did not significantly differ during the first 2 years of the pandemic compared with prior years. In contrast to seasonal influenza, masking and social distancing had no discernable effect on JCV serostatus change.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>38406828</pmid><doi>10.1177/13524585241232274</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2024-06, Vol.30 (7), p.888-892 |
| issn | 1352-4585 1477-0970 1477-0970 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11134982 |
| source | Access via SAGE; MEDLINE |
| subjects | Adult Antibodies, Viral - blood Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - immunology COVID-19 - prevention & control Epidemiology Female Humans Immunologic Factors - therapeutic use JC Virus - immunology Male Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Natalizumab - therapeutic use Pandemics Physical Distancing SARS-CoV-2 - immunology Short Report United States - epidemiology |
| title | The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T17%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20social%20distancing%20measures%20on%20anti%E2%80%93JC%20virus%20serostatus%20changes%20before%20and%20during%20the%20COVID-19%20pandemic%20in%20US%20patients%20with%20multiple%20sclerosis&rft.jtitle=Multiple%20sclerosis&rft.au=Krieger,%20Stephen%20C&rft.date=2024-06-01&rft.volume=30&rft.issue=7&rft.spage=888&rft.epage=892&rft.pages=888-892&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/13524585241232274&rft_dat=%3Cproquest_pubme%3E3061374750%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3061374750&rft_id=info:pmid/38406828&rft_sage_id=10.1177_13524585241232274&rfr_iscdi=true |